lenvatinib mesylate

Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.

Lenvatinib-[D5] (Standard) is a reference standard of Lenvatinib-[D5] intended for quantitative analysis, quality control, and related biochemical research applications.

Lenvatinib (Standard) is a reference standard for research and analysis in studies involving Lenvatinib. Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4/5.2 nM). Lenvatinib has strong anti-tumor activity.

Lenvatinib-D4 is a deuterated compound of Lenvatinib. Lenvatinib (T0520) has a CAS number of 417716-92-8. Lenvatinib (T0520) is a Kinase Inhibitor. The mechanism of action of lenvatinib is as a Receptor Tyrosine Kinase Inhibitor.

Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4/5.2 nM). Lenvatinib has strong anti-tumor activity.

Lenvatinib-D4 (Standard) is a reference standard of Lenvatinib-D4 intended for quantitative analysis, quality control, and related biochemical research applications. Lenvatinib-d4 is a deuterated compound of Lenvatinib. Lenvatinib has a CAS number of 417716-92-8. Lenvatinib is a Kinase Inhibitor. The mechanism of action of lenvatinib is as a Receptor Tyrosine Kinase Inhibitor.